Video: Stem Cell Therapy in Panama with Dr. Riordan and Mel Gibson

Host Michael Beattie discusses stem cell therapy using *human umbilical cord tissue-derived mesenchymal stem cells (hUCT-MSCs)  at the Stem Cell Institute in Panama with renowned applied stem cell scientist and founder, Neil Riordan, Pa, PhD and acclaimed actor, director and producer Mel Gibson.

Dr. Riordan discusses the miraculous progress of a spinal cord injury patient and pilot whose doctors said that he would never walk again.  He talks about where the stem cells come from, how they work and why they can treat so many seemingly different conditions.  Dr. Riordan explains how umbilical cords, and subsequently, hUCT-MSCs used at the Stem Cell Institute are carefully selected using molecular screening.  He also discusses why mesenchymal stem cells from umbilical cords function better than MSCs from adults, especially as they age or if they are suffering from a disease like multiple sclerosis.  For example. MSCs from a newborn multiply exponentially compared to MSCs from an older adult.

Mel Gibson discusses his father’s miraculous recovery, literally from his deathbed after receiving hUCT-MSCs at the age of 92.  He’s currently 99 and still going strong having been treated in Panama several times since then.  Mel also discusses his personal experiences in Panama.

Watch all this and more.

*umbilical cord tissue harvested after normal, healthy births

Why Stem Cells Work: Clinical Trials for Spinal Cord Injury, Multiple Sclerosis, Rheumatoid Arthritis, and Duchenne’s Muscular Dystrophy

Neil Riordan, PhD speaks at the Riordan-McKenna Institute and Stem Cell Institute fall seminar in Southlake, Texas on October 10, 2015.

Dr. Riordan discusses:

  • How our lab selects uses specialized screening techniques to select only the stem cells that we know will be the most useful for our patients. Only about 1 in 100 cords pass this screening process.
  • How umbilical cord mesenchymal stem cells (MSC) control inflammation, modulate the immune system and stimulate regeneration.
  • How the number and function of our own stem cells decline over time.
  • How MSC secretions promote healing
  • Where MSCs are found in our body
  • First clinic trial in the US using umbilical cord tissue-derived stem cells
  • How MSC doubling times dramatically decrease as people age, which is why cord cells are much more robust than a patient’s own cells as they age
  • The origin of Medistem Lab in Panama
  • Why the Stem Cell Institute and Medistem Labs are in Panama
  • Stem cell therapy laws and approvals around the world
  • Global interest in mesenchymal stem cell therapy research
  • Current clinical trials using mesenchymal stem cells
  • Clinical trials in Panama
  • Collaborations with corporations and educational institutions
  • Mesenchymal stem cell selection, donor selection, and testing
  • Brief tour of Medistem Panama stem cell laboratory
  • Isolation and production of mesenchymal stem cells
  • Discovery of mesenchymal stem cells in menstrual blood
  • Umbilical cord mesenchymal stem cell studies for rheumatoid arthritis
  • The role of T-regulatory cells in rheumatoid arthritis and multiple sclerosis
  • Treating spinal cord injuries with mesenchymal stem cells
  • Mechanism of mesenchymal stem cells on spinal cord injury. They are not becoming tissue. It’s their secretions that allow the spinal cord to heal itself.
  • Umbilical cord MSC studies on spinal cord injury
  • Data from Stem Cell Institute spinal cord injury patients
  • Video from treated spinal cord injury patients
  • Postnatal MSC safety
  • MSCs and cancer risk – MSCs have been shows to actually inhibit tumor growth

Clinical Trials for Multiple Sclerosis and Rheumatoid Arthritis using Umbilical Cord Tissue Mesenchymal Stem Cells

Stem Cell Institute and Medistem Panama founder, Neil Riordan, PhD discusses clinical trials for multiple sclerosis and rheumatoid arthritis using umbilical cord tissue-derived mesenchymal stem cells at our fall stem cell seminar in San Antonio.

For more information about these trials and others, please visit www.translationalbiosciences.com. The multiple sclerosis trial is full but the RA trial is still recruiting as of November 24, 2014.

Highlights include:

How do we select umbilical cords for use? Medistem has identified proteins and genes in the cells that allow us to screen hundreds of umbilical cords to select only the ones containing the specific types of cells that have the best anti-inflammatory properties, the best immune modulating capacity and the best ability to stimulate regeneration.

How therapy using umbilical cord tissue-derived mesenchymal stem cells (MSCs) differs from bone marrow transplants used in cancer patients.

Properties of umbilical cord MSCs:

  • Modulate the immune system
  • Increase the number of T-regulatory cells
  • Block clonal expansion of activated T cells
  • MSCs in patients with autoimmune diseases don’t work properly

How demyelination occurs in MS patients and how MSCs act on the immune system to slow it down or stop it.

Treated MS patient follow-up survey results at 120 days and 1 year after treatment.

Television news story about Sam Harrell’s return to coaching football after severe MS symptoms forced him into early retirement.

Results from a 172 patient study on treating rheumatoid arthritis with intravenous umbilical cord tissue mesenchymal stem cells in which all patients improved.

Trial Information

These trials may be viewed on the National Institutes of Health web site www.clinicaltrials.gov

Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis

Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis

Those interested in stem cell therapy for MS may still apply for private treatment on this site.

The Lip TV News: Neil Riordan, PhD on Exploring New Stem Cell Treatments for MS, Arthritis, Autism and More

Stem cell treatment and research towards curing illness–from multiple sclerosis to spinal injury–is detailed by Dr. Neil Riordan. The American medical industry, obstructions to research in the states, misconceptions about stem cells, and the details about the treatment process are explained–and we look at video of patient recovery and speculate at what the future could spell for stem cell treatment and research in this Lip News interview, hosted by Elliot Hill.

GUEST BIO:
Dr. Neil Riordan is the founder and Chairman of Medistem Panama, a leading stem cell laboratory and research facility – located in Panama City. His institute is at the forefront of research of the effects of adult stem cells on the course of several chronic diseases. Dr. Riordan has more than 60 scientific articles in international peer-reviewed journals. In the stem cell arena, he and his colleagues have published more than 20 articles on Multiple Sclerosis, Spinal Cord Injury, Heart Failure, Rheumatoid Arthritis.

Umbilical Cord Stem Cells: Regeneration, Repair, Inflammation and Autoimmunity – Neil Riordan PhD (Part 2 of 2)

In part 2, Dr. Riordan discusses how mesenchymal stem cells can affect tissue repair in spinal cord injury and in heart failure; benefit to heart is not the actual MSCs modeling new tissue. It is due to the trophic effects of MSC secretions; In rats, severed spinal cords re-grew after MSCs were implanted but the human MSCs did not form new cord tissue. The trophic factors secreted by the MSCs enable the spinal cord to repair itself.; Trophic factors from MSCs modulate the immune system by blocking clonal expansion of cytotoxic T-cells; There are 35 ongoing clinical trials using mesenchymal stem cells for autoimmune diseases; Safety of donor MSCs; Every mother has MSCs from each baby she has carried; Mothers have a lower incidence of autoimmune disease; Lifespan of mothers increased linearly with each child up to 14; There are 85 ongoing clinical trials using donor MSCs. Allogeneic MSCs from bone marrow have been approved in Canada and New Zealand to treat graft vs. host disease; limbal cells used in corneal transplants are MSCs; MSCs are useful in preventing donated organ rejection; glioma growth was found to be inhibited by MSCs; MSCs eliminated breast cancer in rats.

Umbilical Cord Mesenchymal Stem Cells: Regeneration, Repair, Inflammation and Autoimmunity – Neil Riordan, PhD (Part 1 of 2)

Neil Riordan, PhD is the Founder of the Stem Cell Institute in Panama. He is also the Co-Founder of Medistem Inc in San Diego and the current President of Medistem Panama. Dr. Riordan is speaking at a Stem Cell Institute patient outreach event held in Miami in May 2013.
In part 1, Dr. Riordan discusses the background of Medistem Panama and the Stem Cell Institute (SCI) in Panama. He presents the types of stem cells used at SCI: Patient’s own bone marrow, Patient’s own fat tissue and umbilical cord mesenchymal stem cells donated from live, healthy births. Dr. Riordans goes on to discuss: collaborations with UC San Diego, Indiana University, University of Utah and University of Western Ontario; patents and publications; Medistem Panama lab, clean rooms and equipment; Why the Stem Cell Institute is in Panama; Panamanian stem cell laws; What are mesenchymal stem cells (MSCs) ?, mesenchymal stem cell homing, how MSCs induce repair, how MSCs modulate the immune system, young vs. old MSCs, Are MSCs safe?; MSCs are actually pericytes. They are found throughout the body in all vascular tissues around blood vessels, bone marrow, umbilical cord, placental tissue, menstrual blood and teeth; Stem Cell Institute’s source of umbilical cord MSCs: live, healthy birth, mother screened for medical history, consent from family for donation, mother tested for infectious diseases, cord tested for infectious diseases and sterility; the mesengenic process; how pericytes respond to injury and form “medicinal MSCs”; MSCs are anti-apoptotic, anti-scaring, angiogenic, and mitotic.; MSCs are also immunomodulatory; MSC homing in rats; Human MSCs decline drastically with age; Stem Cell Institute uses umbilical cord-derived MSCs because they are non-tumorigenic, very robust – high number of doublings, faster doubling time,; What does ‘doubling’ mean?; Effects of aging on MSCs.

Neil Riordan PhD – Stem cell therapy for spinal cord injury (part 5 of 5)

Dr. Riordan discusses current US FDA oversight of adult stem cell treatments, “practice of medicine” treatments that are neither regulated nor approved by the FDA, historical examples of successful medical procedures such as bariatric surgery, liposuction and ulcer treatments which were violently opposed by researchers, physicians and companies with competing financial interests.

2012-11-30T19:06:59+00:00 November 30th, 2012|Neil Riordan PhD, Video - Stem Cell Therapy|

Neil Riordan PhD – Stem cell therapy for spinal cord injury (part 4 of 5)

Dr. Riordan shows a video documenting the progress of a T-12 spinal cord injury patient after her combined bone marrow and umbilical cord stem cell treatment in Panama. He shows another video of a 65 year-old man (T-9) who was treated 13 years after his injury. This case illustrates the potential of treating older people whose injuries occurred many years prior to treatment.

Neil Riordan PhD – Stem cell therapy for spinal cord injury (part 3 of 5)

Mesenchymal stem cell homing to tissue damage, umbilical cord stem cells historically used for anti-aging, mesenchymal stem cells role in immune system modulation, inflammation reduction and stimulating tissue regeneration, donor stem cell safety and testing, the role of HLA matching in donated umbilical cord-derived stem cells, umbilical cord blood safety data and historical use in blood transfusions, allogeneic stem cell persistence in human mothers.

Neil Riordan PhD – Stem cell therapy for spinal cord injury (part 2 of 5)

Case studies of spinal cord injury patients treated with CD34+ and mesenchymal stem cells harvested from human umbilical cord Wharton’s jelly and cord blood, animal studies using mesenchymal stem cells, immunosuppression requirements in allogeneic stem cell treatments, intrathecal and intravenous administration of autologous bone marrow stem cells in spinal cord injury patients, and the role adult stem cell trophic factors in tissue regeneration.